191 related articles for article (PubMed ID: 38811702)
21. Strategies and challenges for the next generation of antibody-drug conjugates.
Beck A; Goetsch L; Dumontet C; Corvaïa N
Nat Rev Drug Discov; 2017 May; 16(5):315-337. PubMed ID: 28303026
[TBL] [Abstract][Full Text] [Related]
22. Linkers Having a Crucial Role in Antibody-Drug Conjugates.
Lu J; Jiang F; Lu A; Zhang G
Int J Mol Sci; 2016 Apr; 17(4):561. PubMed ID: 27089329
[TBL] [Abstract][Full Text] [Related]
23. Immunotoxins and anticancer drug conjugate assemblies: the role of the linkage between components.
Dosio F; Brusa P; Cattel L
Toxins (Basel); 2011 Jul; 3(7):848-83. PubMed ID: 22069744
[TBL] [Abstract][Full Text] [Related]
24. Antibody-Drug Conjugates for Tumor Targeting-Novel Conjugation Chemistries and the Promise of non-IgG Binding Proteins.
Merten H; Brandl F; Plückthun A; Zangemeister-Wittke U
Bioconjug Chem; 2015 Nov; 26(11):2176-85. PubMed ID: 26086208
[TBL] [Abstract][Full Text] [Related]
25. Divinylsulfonamides enable the construction of homogeneous antibody-drug conjugates.
Huang R; Sheng Y; Wei D; Lu W; Xu Z; Chen H; Jiang B
Bioorg Med Chem; 2020 Dec; 28(23):115793. PubMed ID: 33039798
[TBL] [Abstract][Full Text] [Related]
26. Antibody-Drug Conjugates with Pyrrole-Based KSP Inhibitors as the Payload Class.
Lerchen HG; Wittrock S; Stelte-Ludwig B; Sommer A; Berndt S; Griebenow N; Rebstock AS; Johannes S; Cancho-Grande Y; Mahlert C; Greven S; Terjung C
Angew Chem Int Ed Engl; 2018 Nov; 57(46):15243-15247. PubMed ID: 30180286
[TBL] [Abstract][Full Text] [Related]
27. Recent Chemical Approaches for Site-Specific Conjugation of Native Antibodies: Technologies toward Next-Generation Antibody-Drug Conjugates.
Yamada K; Ito Y
Chembiochem; 2019 Nov; 20(21):2729-2737. PubMed ID: 30973187
[TBL] [Abstract][Full Text] [Related]
28. Recent Advances in Site Specific Conjugations of Antibody Drug Conjugates (ADCs).
Gao W; Zhang J; Xiang J; Zhang L; Wu C; Dhal PK; Chen B
Curr Cancer Drug Targets; 2016; 16(6):469-79. PubMed ID: 27174056
[TBL] [Abstract][Full Text] [Related]
29. Antibody-drug conjugates: the new generation of biotechnological therapies against cancer.
Melgarejo-Rubio G; Pérez-Tapia SM; Medina-Rivero E; Velasco-Velázquez MA
Gac Med Mex; 2020; 156(3):228-235. PubMed ID: 32538994
[TBL] [Abstract][Full Text] [Related]
30. Comprehensive review on the elaboration of payloads derived from natural products for antibody-drug conjugates.
Lu N; Wu J; Tian M; Zhang S; Li Z; Shi L
Eur J Med Chem; 2024 Mar; 268():116233. PubMed ID: 38408390
[TBL] [Abstract][Full Text] [Related]
31. Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates.
Donaghy H
MAbs; 2016; 8(4):659-71. PubMed ID: 27045800
[TBL] [Abstract][Full Text] [Related]
32. Using the Lessons Learned From the Clinic to Improve the Preclinical Development of Antibody Drug Conjugates.
Jackson D; Stover D
Pharm Res; 2015 Nov; 32(11):3458-69. PubMed ID: 25339341
[TBL] [Abstract][Full Text] [Related]
33. Pyrrolobenzodiazepine Dimer Antibody-Drug Conjugates: Synthesis and Evaluation of Noncleavable Drug-Linkers.
Gregson SJ; Masterson LA; Wei B; Pillow TH; Spencer SD; Kang GD; Yu SF; Raab H; Lau J; Li G; Lewis Phillips GD; Gunzner-Toste J; Safina BS; Ohri R; Darwish M; Kozak KR; Dela Cruz-Chuh J; Polson A; Flygare JA; Howard PW
J Med Chem; 2017 Dec; 60(23):9490-9507. PubMed ID: 29112410
[TBL] [Abstract][Full Text] [Related]
34. Antibody-Drug Conjugates for Cancer Therapy.
Hafeez U; Parakh S; Gan HK; Scott AM
Molecules; 2020 Oct; 25(20):. PubMed ID: 33081383
[TBL] [Abstract][Full Text] [Related]
35. Antibody-drug conjugates: using monoclonal antibodies for delivery of cytotoxic payloads to cancer cells.
Goldmacher VS; Kovtun YV
Ther Deliv; 2011 Mar; 2(3):397-416. PubMed ID: 22834009
[TBL] [Abstract][Full Text] [Related]
36. Bispecific Antibodies and Antibody-Drug Conjugates for Cancer Therapy: Technological Considerations.
Shim H
Biomolecules; 2020 Feb; 10(3):. PubMed ID: 32111076
[TBL] [Abstract][Full Text] [Related]
37. Antibody-DM1 conjugates as cancer therapeutics.
Lopus M
Cancer Lett; 2011 Aug; 307(2):113-8. PubMed ID: 21481526
[TBL] [Abstract][Full Text] [Related]
38. Bioanalysis special focus issue on antibody-drug conjugates.
Kaur S
Bioanalysis; 2013 May; 5(9):981-3. PubMed ID: 23641688
[No Abstract] [Full Text] [Related]
39. Tubulin Inhibitor-Based Antibody-Drug Conjugates for Cancer Therapy.
Chen H; Lin Z; Arnst KE; Miller DD; Li W
Molecules; 2017 Aug; 22(8):. PubMed ID: 28763044
[TBL] [Abstract][Full Text] [Related]
40. Trends in cancer-targeted antibody-drug conjugates.
Bidard FC; Trédan O
Target Oncol; 2014 Mar; 9(1):1-8. PubMed ID: 24221961
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
